Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease by Kunrong Yu, Wanying Li, Wenjie Long, Yijia Li, Yanting Li, Huili Liao, Jianhong Liu

“…Abstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating protein biomarkers for ILD and its subtypes. …”
Get full text

Comparative Study of Ectopic Lymphoid Aggregates in Sheep and Murine Models of Bleomycin-Induced Pulmonary Fibrosis by Udari Eshani Perera, Louise Organ, Simon G. Royce, Chrishan S. Samuel, Habtamu B. Derseh, Sasika N. V. Dewage, Emmanuel Koumoundouros, Andrew Stent, Kenneth J. Snibson

“…Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterized by excessive deposition of extracellular matrix in the interstitial lung parenchyma, often manifested by dyspnea and progressive loss of lung function. …”
Get full text

The Role of PPARs in Lung Fibrosis by Heather F. Lakatos, Thomas H. Thatcher, R. Matthew Kottmann, Tatiana M. Garcia, Richard P. Phipps, Patricia J. Sime

“…For example, patients with idiopathic pulmonary fibrosis (IPF) have a median survival of only 2.9 years. …”
Get full text

The Protective Effect of Naringin against Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats by Nergiz H. Turgut, Haki Kara, Sahende Elagoz, Koksal Deveci, Huseyin Gungor, Emre Arslanbas

“…These results show that naringin has the potential of reducing the toxic effects of bleomycin and may provide supportive therapy for conventional treatment methods for idiopathic pulmonary fibrosis.…”
Get full text

Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study by Haifeng Yu, Xiaofei Zhang, Bian Wen, Shuo Hu, Bin Ni

“…RESULTS Our study did not find any significant association between genetically proxied APOB, CETP, HMGCR, NPCIL, PCSK9, and LDLR inhibition (equivalent to a one standard deviation reduction in LDL-C) with the risk of Small Cell Lung Cancer, Non-Small Cell Lung Cancer, idiopathic pulmonary fibrosis, and Pneumonia (P > 0.05). However, long-term inhibition of NPC1L that mimics the use of statin drugs may have contradictory effects on pulmonary edema (OR = 0.508, 95%CI = 0.328–0.786,P = 0.002) and chronic obstructive pulmonary disease (OR = 1.524, 95%CI = 1.099–2.115, P = 0.012). …”
Get full text

Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives by C. Randall Harrell, Ruxana Sadikot, Jose Pascual, Crissy Fellabaum, Marina Gazdic Jankovic, Nemanja Jovicic, Valentin Djonov, Nebojsa Arsenijevic, Vladislav Volarevic

“…In this review article, we described molecular mechanisms involved in MSC-based therapy of acute and chronic pulmonary diseases and emphasized current knowledge and future perspectives related to the therapeutic application of MSCs in patients suffering from acute respiratory distress syndrome, pneumonia, asthma, chronic obstructive pulmonary diseases, and idiopathic pulmonary fibrosis.…”
Get full text

Global scenario of silica-associated diseases: A review on emerging pathophysiology of silicosis and potential therapeutic regimes by Prasad Sherekar, Sanvidhan G. Suke, Archana Dhok, Srikant Malegaonkar, Shrikrishna A. Dhale

“…Other crystalline silica-induced pulmonary disorders include a predisposition to mycobacterial infections, obstructive airway diseases, idiopathic pulmonary fibrosis, and lung cancer. This review paper discusses the burden of silicosis and associated co-morbidities in developed as well as developing countries globally using the published data of various government agencies, related organizations, and epidemiological findings. …”
Get full text

A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography by Shu Hisata, Yuichiro Kimura, Naoko Shibata, Shuichi Ono, Takao Kobayashi, Shigeki Chiba, Hiromitsu Ohta, Toshihiro Nukiwa, Masahito Ebina

“…Both SP-D and KL-6/MUC1 are established biomarkers of the interstitial pneumonias, including idiopathic pulmonary fibrosis (IPF), but the causes and clinical outcomes based on their independent effects are not known. …”
Get full text

Do We Need Exercise Tests to Detect Gas Exchange Impairment in Fibrotic Idiopathic Interstitial Pneumonias? by Benoit Wallaert, Lidwine Wemeau-Stervinou, Julia Salleron, Isabelle Tillie-Leblond, Thierry Perez

“…Results were obtained in 121 patients with idiopathic pulmonary fibrosis (IPF, n=88) and fibrotic nonspecific interstitial pneumonias (NSIP, n=33). …”
Get full text

The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study by Narongkorn Saiphoklang, Pimchanok Patanayindee, Pitchayapa Ruchiwit

“…Lung fibrosis is a sequela of COVID-19 among patients with severe pneumonia. Idiopathic pulmonary fibrosis and lung fibrosis due to COVID-19 may share many similar features. …”
Get full text

Malondialdehyde in Exhaled Breath Condensate as a Marker of Oxidative Stress in Different Pulmonary Diseases by M. L. Bartoli, F. Novelli, F. Costa, L. Malagrinò, L. Melosini, E. Bacci, S. Cianchetti, F. L. Dente, A. Di Franco, B. Vagaggini, P. L. Paggiaro

“…We measured MDA levels in EBC in a large number of patients (N=194) with respiratory diseases: asthma (N=64), bronchiectasis (BE, N=19), chronic obstructive pulmonary disease (COPD, N=73), idiopathic pulmonary fibrosis (IPF, N=38). Fourteen healthy nonsmoking subjects were included as controls. …”
Get full text

Nano-XRF of lung fibrotic tissue reveals unexplored Ca, Zn, S and Fe metabolism: a novel approach to chronic lung diseases by Bryan Falcones, Maik Kahnt, Ulf Johansson, Barbora Svobodová, Karin A. von Wachenfelt, Charlott Brunmark, Göran Dellgren, Linda Elowsson, Karina Thånell, Gunilla Westergren-Thorsson

“…In the context of Idiopathic Pulmonary Fibrosis (IPF), a debilitating lung condition associated with respiratory complications and reduced life expectancy, nano-XRF presents a promising avenue for understanding the disease’s intricate pathology. …”
Get full text

Qingfei Tongluo Mixture Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis through mTOR-Dependent Autophagy in Rats by Shuyu Ge, Zhenghong Guo, Ting Xiao, Pingping Sun, Bo Yang, Yin Ying

“…As an interstitial fibrosis disease characterized by diffuse alveolitis and structural alveolar disorders, idiopathic pulmonary fibrosis (IPF) has high lethality but lacks limited therapeutic drugs. …”
Get full text

Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis. by Mei Yang, Yuying Tan, Ting Yang, Dan Xu, Mei Chen, Lei Chen

“…<h4>Background</h4>The therapeutic role of antifibrotic therapy has been well-established in idiopathic pulmonary fibrosis (IPF). However, its efficacy and safety for interstitial lung diseases (ILDs) other than IPF are not fully understood.…”
Get full text

Supporting self-management for patients with Interstitial Lung Diseases: Utility and acceptability of digital devices. by Malik A Althobiani, Rebecca Shuttleworth, John Conway, Jonathan Dainton, Anna Duckworth, Ana Jorge Da Ponte, Jessica Mandizha, Joseph W Lanario, Michael A Gibbons, Sarah Lines, Chris J Scotton, John R Hurst, Joanna C Porter, Anne-Marie Russell

“…<h4>Results</h4>104 patients accessed the survey and 89/104 (86%) reported a diagnosis of lung fibrosis, including 46/89 (52%) idiopathic pulmonary fibrosis (IPF) with 57/89 (64%) of participants diagnosed >3 years and 59/89 (66%) female. 52/65(80%) were in the UK; 33/65 (51%) reported severe breathlessness medical research council MRC grade 3-4 and 32/65 (49%) disclosed co-morbid arthritis or joint problems. …”
Get full text

Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease by Osamu Nishiyama, Ryo Yamazaki, Hiroyuki Sano, Takashi Iwanaga, Yuji Higashimoto, Hiroaki Kume, Yuji Tohda

“…Forty-six patients consisting of 20 with idiopathic pulmonary fibrosis, 14 with collagen vascular disease associated ILD, and 12 with other idiopathic interstitial pneumonia were recruited (mean % predicted FVC: 76.7±17.1%). …”
Get full text

The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases by Ghofran Ageely, Carolina Souza, Kaissa De Boer, Saly Zahra, Marcio Gomes, Nha Voduc

“…Overall agreement for specific pre-MDD and MDD diagnosis was 41% (52/126) and 80% for idiopathic pulmonary fibrosis (IPF) diagnosis. MDD altered diagnosis in 37% (47/126) and changed management in 39% (50/126). …”
Get full text

Cloned airway basal progenitor cells to repair fibrotic lung through re-epithelialization by Yu Zhao, Yueqing Zhou, Weipan Zhang, Mingzhe Liu, Jun Duan, Xiaopeng Zhang, Qiwang Ma, Yujia Wang, Yuzhen Zhang, Zhongliang Guo, Ting Zhang, Wei Zuo

“…Abstract Irreversible damage of the lung epithelium in idiopathic pulmonary fibrosis (IPF) patients causes high mortality worldwide, with no lung repair approaches available currently. …”
Get full text

Features and predictive value of 6-min walk test outcomes in interstitial lung disease: an observation study using wearable monitors by Jiaying Li, Xiaobing Wu, Xiaoyan Li, Miaozhen Deng, Xinyin Liang, Huiqun Wei

“…Objectives To describe 6-min walk test (6MWT) outcomes, and to investigate their correlations with cardiopulmonary and lung function among patients with interstitial lung disease (ILD) which was not limited to idiopathic pulmonary fibrosis.Methods We collected patients’ demographic data and obtained minute-by-minute 6MWT outcomes. …”
Get full text

European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD). by Ekaterina Krauss, Laurenz H Claas, Silke Tello, Jennifer Naumann, Sandra Wobisch, Stefan Kuhn, Raphael W Majeed, Karen Moor, Maria Molina-Molina, Oisin Byrne, Rebecca Borton, Marlies S Wijsenbeek, Nik Hirani, Carlo Vancheri, Bruno Crestani, Andreas Guenther, eurILDreg investigators

“…<h4>Background and aims</h4>Predicting progression and prognosis in Interstitial Lung Diseases (ILD), especially Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), remains a challenge. …”
Get full text